Analyst Sentiment Shifts as Ocugen Gains Second Major Backer

The investment thesis for biopharmaceutical company Ocugen is gaining notable support on Wall Street. In a significant endorsement, the firm has secured coverage from a second major investment bank within a short timeframe. Canaccord Genuity recently initiated coverage with a Buy rating, assigning a $12 price target. This projection implies a substantial upside potential of approximately 390% from the stock’s trading level in mid-March.

Clinical Pipeline Draws Scrutiny and Optimism

The catalyst for this growing analyst interest is rooted in tangible clinical progress. In early March, Ocugen completed patient enrollment for its Phase 3 liMeliGhT trial for OCU400, having recruited 140 participants. Topline results from this study are anticipated in the first quarter of 2027, with a rolling Biologics License Application (BLA) submission planned for Q3 2026. Notably, the European Medicines Agency has agreed to accept data from this U.S.-based trial for a potential marketing application.

Further bolstering the outlook are developments across its other gene therapy candidates. For the OCU410 program targeting geographic atrophy, a preliminary 12-month analysis from the Phase 2 ArMaDa study showed a 46% reduction in lesion growth with a 50% response rate, and no serious safety events were reported. The complete dataset from this trial is expected in March 2026. Meanwhile, interim data for OCU410ST in Stargardt disease are scheduled for the third quarter of 2026.

Canaccord analyst Whitney Ijem cited the company’s pipeline of AAV-based gene therapy candidates for retinal diseases as the basis for the bullish stance. The bank described data across all three clinical programs as “interesting” and views the expected Q3 2026 data readouts as potential de-risking events for the company.

A Consensus Begins to Form

This latest analysis adds to a series of positive initiations. Oppenheimer began coverage on March 11 with an Outperform rating and a $10 price target. Chardan Capital has maintained a Buy rating with a $7 target since early March. Across the five analysts now covering the equity, the average price target stands at $9.60, within a range of $7 to $15.

Should investors sell immediately? Or is it worth buying Ocugen?

Financial Resilience Remains a Key Focus

Despite the clinical advancements, Ocugen’s financial position requires careful monitoring. The company reported a net loss of $67.8 million for the full year 2025, against revenue of just $4.4 million, which was primarily derived from licensing agreements. Its cash and equivalents totaled $18.6 million at year-end.

A capital raise of $22.5 million in January 2026 has extended the company’s financial runway into the fourth quarter of 2026. If all outstanding warrants are fully exercised, this liquidity could potentially stretch into Q2 2027. However, a negative shareholders’ equity position of $12.2 million and a narrow funding buffer highlight that any clinical setback could necessitate further, potentially dilutive, financing measures.

Institutional investors appear to be weighing these risks against the potential rewards. Major firms including Vanguard and Millennium Management meaningfully increased their holdings in Ocugen during the fourth quarter of 2025, even amidst the challenging balance sheet.

With the complete ArMaDa data set imminent and OCU410ST interim results due mid-year, the coming months will test whether Wall Street’s growing conviction is built upon a solid clinical foundation.